Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

CATALYST investigators, Benjamin Fisher, Tonny Veenith, Daniel Slade, Charlotte Gaskell, Matthew Rowland, Tony Whitehouse, James Scriven, Dhruv Parekh, Madhu Balasubramaniam, Graham Cooke, Nick Morley, Zoe Gabriel, Matthew Wise, Joanna Porter, Helen McShane, Ling-Pei Ho, Philip Newsome, Anna Rowe, Rowena SharpeDavid Thickett, Julian Bion, Simon Gates, Duncan Richards, Pamela Kearns

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial'. Together they form a unique fingerprint.

Medicine & Life Sciences